Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation

exactis

Sermonix Pharmaceuticals’ study “Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation.”

The clinical trial is ongoing in the United States, and Exactis is currently performing a feasibility assessment across Canada to identify sites interested in participating in the study, if interested please contact dsalazar@exactis.ca

https://clinicaltrials.gov/ct2/show/NCT03781063?term=sermonix&draw=2&rank=1